Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study.

Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM.

Heart. 2002 Mar;87(3):229-34.

2.

Association between allopurinol and mortality in heart failure patients: a long-term follow-up study.

Wei L, Fahey T, Struthers AD, MacDonald TM.

Int J Clin Pract. 2009 Sep;63(9):1327-33. doi: 10.1111/j.1742-1241.2009.02118.x.

PMID:
19691616
3.

Impact of allopurinol use on urate concentration and cardiovascular outcome.

Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM.

Br J Clin Pharmacol. 2011 Apr;71(4):600-7. doi: 10.1111/j.1365-2125.2010.03887.x.

4.

[Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].

Ohno I, Okabe H, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Gomi H, Ichida K, Hosoya T.

Nihon Jinzo Gakkai Shi. 2008;50(4):506-12. Japanese.

PMID:
18546882
5.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090
6.

Gout, allopurinol use, and heart failure outcomes.

Thanassoulis G, Brophy JM, Richard H, Pilote L.

Arch Intern Med. 2010 Aug 9;170(15):1358-64. doi: 10.1001/archinternmed.2010.198.

PMID:
20696962
7.

Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.

Málek F, Ošťádal P, Pařenica J, Jarkovský J, Vítovec J, Widimský P, Linhart A, Fedorco M, Coufal Z, Miklík R, Krűger A, Vondraková D, Špinar J.

J Crit Care. 2012 Dec;27(6):737.e11-24. doi: 10.1016/j.jcrc.2012.03.011.

PMID:
22699032
8.

Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.

So MW, Lee SG, Kim YG, Lee CK, Yoo B.

Scand J Rheumatol. 2011 Nov;40(6):444-7. doi: 10.3109/03009742.2011.589033.

PMID:
21916803
9.

Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.

Kok VC, Horng JT, Chang WS, Hong YF, Chang TH.

PLoS One. 2014 Jun 4;9(6):e99102. doi: 10.1371/journal.pone.0099102.

10.

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO.

Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126.

11.

Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R.

Ann Pharmacother. 2006 Mar;40(3):386-91.

PMID:
16478808
12.

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.

Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA.

Rheumatology (Oxford). 2003 Feb;42(2):321-5.

13.

Relation between adverse events associated with allopurinol and renal function in patients with gout.

Vázquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R.

Ann Rheum Dis. 2001 Oct;60(10):981-3.

14.

Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.

Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM.

Arthritis Rheum. 2006 Oct 15;55(5):786-90.

15.
16.

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees..

Circulation. 2004 Oct 26;110(17):2618-26.

17.

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93. doi: 10.2215/CJN.01580210.

18.
19.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107
20.

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Chao J, Terkeltaub R.

Curr Rheumatol Rep. 2009 Apr;11(2):135-40. Review.

PMID:
19296886
Items per page

Supplemental Content

Support Center